19 results about "Linked protein" patented technology

The invention provides a double-layer collagen scaffold repair membrane as well as a preparation method and application thereof, and the preparation method comprises the following steps: extracting collagen from animal fur, and emulsifying to obtain a collagen emulsion; adding a cross-linking agent into the collagen emulsion, and emulsifying to obtain a cross-linked protein emulsion; pouring the cross-linked protein emulsion into a mold, and freeze-drying to obtain a cross-linked protein layer; and pouring the collagen emulsion on the cross-linked protein layer, and freeze-drying to obtain the double-layer collagen scaffold repair membrane. The repairing membrane is excellent in structure, the cross-linked protein layer provides mechanical strength and supporting performance, the collagen layer can be rapidly dissolved and attached to the contact surface, and oxygen exchange and metabolite discharge of the wound surface are facilitated; the collagen is high in purity, low in antigenicity and high in safety, any toxic and harmful chemical reagents and preservatives are not added, allergy or inflammatory reaction is avoided, and the collagen has good application prospects in the fields of medical treatment, medical beauty, beauty, skin care and the like.

Provided are a Blumea balsamifera monoterpene synthase BbTPS3 and related biological materials thereof and use thereof. BbTPS3 is: A1) a protein having the amino acid sequence shown in SEQ ID NO: 2; A2) a fusion protein obtained by linking protein-tags at the N-terminus or / and the C-terminus of the protein shown in SEQ ID NO: 2; and A3) a protein having at least 90% identity and the same function as the protein shown in A1), which is obtained by performing substitution and / or deletion and / or addition of one or more amino acid residues on the amino acid sequence shown in SEQ ID NO: 2. BbTPS3 can catalyze GPP to form l-borneol, and can be used to regulate and produce plant monoterpene compounds and cultivate Blumea balsamifera (L.) DC.

The invention relates to the technical field of vascular therapy, in particular to a nano-drug and a preparation method thereof.The nano-drug comprises a nano-carrier, a therapeutic drug and cross-linked protein are loaded on the nano-carrier, the cross-linked protein is at least partially loaded on the surface of the nano-carrier, and the cross-linked protein is at least one of silk fibroin, sericin and silk fibroin peptide; the therapeutic drug is at least partially loaded in the nano-carrier. On one hand, cross-linked protein on the surface of the nano-carrier is promoted to be cross-linked with protein in a blood vessel by initiating the photosensitive cross-linking agent, and the nano-carrier is anchored in the blood vessel, so that the risk that nano-drug particles are eluted from the blood vessel wall is greatly reduced; on the other hand, cross-linking of cross-linked protein on the surface of the nano-carrier can be promoted by initiating the photosensitive cross-linking agent, so that the surface of the nano-carrier is gelatinized, the slow release speed of the nano-drug anchored in the blood vessel is more lasting, and further effective drug concentration can be maintained for a long time, restenosis of the blood vessel is inhibited, and the treatment effect is improved.

The invention discloses a sequential enzymatic-ionic synergistic soybean protein isolate modification method, which comprises the following steps: dispersing soybean protein isolate in water to prepare a protein solution, adding glutamine transaminase, carrying out heating reaction to inactivate enzyme to obtain an enzyme cross-linked protein solution, adding MgCl2 into the enzyme cross-linked protein solution, and carrying out heating reaction to induce protein aggregation to obtain a modified soybean protein isolate solution; and cooling to room temperature after the reaction is finished. The invention also discloses an application of the soybean protein product obtained by the sequential enzymatic-ionic synergistic soybean protein isolate modification method as a food additive. According to the method, the sensitization of the soybean protein can be remarkably reduced, meanwhile, the unique stomach resistance-intestinal efficient release dynamic characteristic is shown, and the small intestine peptide fragment release amount is promoted to be increased.

This invention belongs to the food field, specifically relating to a hypoallergenic, gluten-free, non-wheat tiger nut fermented noodle product and its preparation method. The hypoallergenic, gluten-free, non-wheat tiger nut fermented noodle product comprises the following components: raw material powder, alkaline protease, transglutaminase, additives, and water; the raw material powder is a mixture of tiger nut meal powder and rice flour. The technical solution of this application utilizes a fermentation system using alkaline protease and transglutaminase. Alkaline protease hydrolyzes the amide and peptide bonds of proteins, causing acylation reactions that cross-link protein molecules, producing a network structure and improved flavor and quality. Transglutaminase catalyzes the acylation reaction between the amide group in glutamine and the ε-amino group on lysine peptides, causing cross-linking of protein molecules to form the target protein and produce the desired product.

Compounds, proteins, crosslinked proteins, compositions thereof, and methods of making and uses thereof. A compound, which may be an alpha-amino acid, comprises one or more beta-lactam group(s), one or more triazole groups, substituted analogs thereof, or any combination thereof. A protein comprises one or more amino acid residue(s), each residue comprising a beta-lactam group, a triazole group, or a substituted analog thereof. A protein can be made by a recombinant method using one or more compound(s). A cross-linked protein comprises one or more intramolecular crosslink(s) and / or one or more intermolecular crosslink(s). In various examples, a crosslink is formed, e.g., in solution or in vivo, by a proximity enabled beta-lactam ring opening reaction or an acyl transfer reaction between a beta-lactam group or a triazole group and a nucleophilic side-chain group, where both groups are on a single polypeptide or on different polypeptide chains. Crosslinked protein(s) can be used in methods of treatment.

In one embodiment, the present invention provides a composition, wherein the composition is a porous scaffold, wherein the pores of the scaffold are from 2 to 500 microns, the composition comprising: a) a cross-linkable protein selected from the group consisting of collagen and gelatin; b) a cross-linker which induces cross-linking of the cross-linkable protein; and c) a liquid.

In one embodiment, the present invention provides a composition, wherein the composition is a porous scaffold, wherein the pores of the scaffold are from 1 to 500 microns, the composition comprising: a) a cross-linkable protein selected from the group consisting of collagen and gelatin; b) a cross-linker which induces cross-linking of the cross-linkable protein; and c) a liquid.

The invention relates to a BCG (Bacillus Calmette Guerin)-loaded floating protein microbubble and application thereof in perfusion therapy of bladder cancer. The invention discloses a BCG (Bacillus Calmette Guerin)-loaded floating protein microbubble. The BCG-loaded floating protein microbubble comprises a shell structure and an inner-layer gas nucleus structure, the shell structure is a cross-linked protein layer skeleton, the surface of the cross-linked protein layer skeleton is modified with hexadecyl trimethyl ammonium bromide, and BCG is loaded on the surface of the cross-linked protein layer skeleton under the action of the BCG and the hexadecyl trimethyl ammonium bromide. The gas filled in the inner layer can realize stable floating of the protein microvesicles in the bladder; the outer layer is loaded with the bacillus calmette-guerin vaccine, and controllable release of the bacillus calmette-guerin vaccine can be achieved under the condition of natural degradation or ultrasonic stimulation; meanwhile, gas in the microbubbles and a crosslinked protein shell form an ultrasonic impedance difference interface, and visualization of drug carrier distribution under ultrasound is achieved. Therefore, the floating protein microbubble can enhance the local immune stimulation effect in the bladder by prolonging the residence time and the controllable release characteristic of the BCG, and an innovative solution integrating in-situ long-time residence, visual monitoring, drug controlled release and long-acting treatment is provided for bladder cancer perfusion immunotherapy.

The invention relates to the technical field of food preservation, and provides a tapioca pearl preservative as well as a preparation method and application thereof, and the tapioca pearl preservative comprises casein, chymosin, food-grade calcium salt, a bacteriostatic agent and water. The preparation method of the tapioca pearl preservative comprises the following steps: (1) adding casein, chymosin and food-grade calcium salt into water, heating and stirring to obtain a solution A; and (2) adding a bacteriostatic agent into the solution A, stirring and dissolving to form the tapioca pearl preservative. When in use, the tapioca pearls preservative is sprayed on the surfaces of tapioca pearls and then dried, a layer of enzymatic cross-linked protein film activated by calcium ions can be formed on the surfaces of tapioca pearls, and the film has double functions of physical barrier and chemical bacteriostasis, so that long-acting preservation is realized, and the tapioca pearls preservative has the advantages of high safety, long preservation period, low cost and the like. And the fresh-keeping method is suitable for fresh-keeping treatment of industrial production of tapioca pearls.

The invention relates to an expression vector operable in vertebrate liver cells, having an expression cassette with a bidirectional promoter, driving operably linked protein expression by a first side and a second side, a first expression unit, under the control of the first side of the promoter, said first expression unit comprising a positive selectable marker gene, a second expression unit, under the control of the second side of the promoter, comprising an ORFeus reporter element wherein said ORFeus reporter element comprises a gene encoding L1-ORF land a retrotransposition reporter gene encoding a retrotransposition reporter protein, wherein preferably the retrotransposition reporter protein from said retrotransposition reporter gene is provided only when the ORFeus reporter element is subject to retrotransposition. The invention also relates to transgenic animals which are useful to detect somatic retrotransposition.

The invention belongs to the technical field of food processing, and particularly relates to a microcapsule gradient cross-linked protective protein jelly thickening agent and a jelly low-temperature production process, and the thickening agent comprises the following components in percentage by mass: 20-25% of carrageenan, 10-20% of starch, 10-20% of starch, 10-20% of starch, 10-20% of starch, and the balance of water. The mass ratio of the carrageenan to the konjac gum is (1: 0.8)-(1: 1.2); 10%-15% of calcium alginate microencapsulated colloid, wherein the microencapsulated colloid wraps the whey protein or the soybean protein isolate; wherein the calcium alginate microencapsulated colloid can also be used for wrapping probiotics or fat-soluble vitamins and the like. Through a micro-capsule gradient cross-linking technology and low-temperature process innovation, the comprehensive performance of a jelly product is remarkably improved, thermosensitive active ingredients are wrapped by adopting a calcium alginate microencapsulation technology, oxidative degradation is inhibited in combination with a natural antioxidant, the activity of functional ingredients such as protein and probiotics is effectively protected under the conditions of low-temperature processing and ultrahigh-pressure sterilization, and the jelly has the beneficial effects of being free of toxic and side effects and the like. And the problem of component inactivation caused by a traditional high-temperature process is avoided.

The invention belongs to the technical field of biomedical materials, and particularly relates to a multi-crosslinked protein preparation method, a product and application. The preparation method comprises the following steps: dissolving a collagen sample in a buffer solution, adding an antioxidant, and carrying out ultrasonic treatment to obtain a collagen solution; then adding dithio bismaleimide into the collagen solution, and stirring to form a first cross-linked protein; adding a cross-linking agent mixture into the primary cross-linked protein to form secondary cross-linked protein; and finally, adding ethylene glycol dimethacrylate and a photoinitiator into the double-crosslinked protein, uniformly stirring, and dialyzing to obtain the photoinitiator. The multi-crosslinked protein prepared by the invention has better crosslinking degree, cell survival rate and in-vitro degradation half-life period, the adopted crosslinking agent is safe and non-toxic, and the multi-crosslinked protein is suitable for skin fillers, tissue engineering scaffolds, wound dressings and other scenes with high requirements on biocompatibility.

The application provides a cytoskeleton modeling method based on dissipative particle dynamics simulation, comprising the following steps: step 1, setting a cell region in a dissipative particle dynamics simulation software; step 2, randomly distributing microfilament single chains which do not intersect each other in the cell region; step 3, randomly generating a plurality of free cross-linking protein particles in the cell region; step 4, the microfilament single chains and the cross-linking protein particles are polymerized / dissociated until the number of the cross-linking protein particles in three states tends to be stable, the three states of the cross-linking protein particles are free, combined with only one microfilament single chain and combined with two microfilament single chains; step 5, deleting the cross-linking protein particles and directly connecting two microfilament single chains connected by the same cross-linking protein particle; and step 6, calculating cytoskeleton parameters and outputting a cytoskeleton model. The cytoskeleton constructed by the application has high fidelity and presents mechanical characteristics such as viscoelasticity under the action of an external force.

This application relates to the field of bioactive peptide preparation technology, and discloses a method for preparing a blood pressure-lowering protein active peptide composition. The raw materials for this composition include a protein substrate, deionized water, alkaline protease, a complex solubilizing buffer, and a cross-linked aqueous solution containing sodium hexametaphosphate. The preparation method includes: isothermal enzymatic hydrolysis of the protein substrate; adding the complex solubilizing buffer to the hydrolysate and instantaneously heating it to construct a steric hindrance protective layer for the short peptides; subsequently injecting the cross-linked aqueous solution for high-shear cross-linking, allowing large molecular impurities to target and bind; and then directly spraying it into a vacuum flash evaporator for rapid cooling, causing the cross-linked protein network to shrink and densify; finally, centrifugation, ultrafiltration, concentration, and drying are performed to obtain the finished product. This invention prevents the active short peptides from co-precipitating with impurities under heat, effectively maintaining the blood pressure-lowering activity of the peptides, and densifying the impurity flocs, thereby improving the separation and sludge removal efficiency and the anti-fouling ability of the ultrafiltration membrane.

Methods for making hemoglobin based blood substitute preparations and hemoglobin based blood substitute preparations. The methods involve preparing a low purity erythrocyte protein fraction comprising hemoglobin protein and endogenous non-hemoglobin protein complement, and chemically modifying the proteins in the protein fraction to form a cross-linked hemoglobin containing blood substitute preparation. The low purity erythrocyte protein preparation can contain from at least about 0.2% (mole / mole) up to about 20% (mole / mole) endogenous non-hemoglobin protein complement. At least about 90% (mole / mole) of the hemoglobin proteins can be cross-linked, so that the average molecular mass of cross-linked proteins comprising hemoglobin protein molecules in the preparation is at least about 300 kDa. The preparations can be used to prepare finished blood substitute formulations for in-vivo and ex-vivo use.

The invention relates to a process for treating a protein-containing composition. The process includes the provision of a protein-containing composition wherein the proteins comprise milk proteins and said milk proteins comprise at least 90 wt. % β-lactoglobulins. The composition is contacted with a transglutaminase to obtain a cross-linked protein-containing composition. This process enhances not only the heat stability, in particular in presence of calcium but also the texture properties of such protein-containing compositions. The invention also relates to cross-linked protein-containing compositions obtainable or obtained by said process, to a process for preparing dairy products or alternatives thereof with such compositions and to the resulting dairy products or alternatives thereof.

The invention discloses polypeptide type micromolecule glue and application thereof in preparation of cosmetics with a skin anti-aging effect. The polypeptide type small molecule glue comprises a hyaluronic acid binding peptide fragment and a proteoglycan binding peptide fragment. The polypeptide type small molecule glue provided by the invention is polypeptide with biological activity, the polypeptide can be combined with hyaluronic acid and proteoglycan after entering cells, the function of connecting the hyaluronic acid and the proteoglycan to protein 1 (HAPLN1) can be replaced, the content of collagen which is gradually reduced along with skin aging can be recovered to a certain extent, and the collagen type small molecule glue has the advantages of being good in biocompatibility, good in stability and good in stability. The composition may become a promising innovative strategy for preventing or repairing the aged skin.

The invention discloses an application of OLA1 in preparation of a medicine for inhibiting vascular endothelial penetration, and belongs to the technical field of biological medicine, in a primary HUVECs cell knockout or overexpression OLA1 stable transfection cell line, through an immunofluorescence experiment, a Transwell endothelial permeability determination experiment and a fluorescein scratch experiment, it is found that when OLA1 is inhibited, connection between cells is tighter; in-vivo experiments show that through caudal vein injection of Evans Blue and collection of mouse tissues, it is found that the vascular permeability of an Ola1 knockout mouse is weakened compared with a control group, and Ola1 gene knockout can inhibit the vascular endothelial permeability in the mouse body; in primary HUVECs (human umbilical vein endothelial cells) with OLA1 knocked out, intercellular chained protein VE-Cadherin is detected through immunofluorescence, and the situation that the permeability of thrombin-induced endothelial cells is reduced by knocking out the OLA1 is found.